© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
February 2022
From the Editor-in-Chief: From the Earth to the Moon (and Back)
February 16, 2022
Article
FROM THE EDITORS
The president’s aim is a 50% reduction in age-adjusted cancer deaths by 2047. This goal seems audacious, but it is likely achievable.
With Approval for Axi-cel in Second-line on the Horizon, CAR T-Cell Therapy Poised to Enter New Phase
February 14, 2022
Article
COVER FEATURE
Lessons from the early days of chimeric antigen receptor (CAR) T-cell therapy remain fresh as Kite Pharma prepares for the FDA to act on its supplemental biologics license application for use of axi-cel as second-line therapy in relapsed or refractory large B-cell lymphoma. A target action date is set for April 1, 2022.
Telehealth at Minnesota Oncology: Tackling COVID-19, Educating Patients, and Overcoming the Weather
February 14, 2022
Article
COVER FEATURE
Rajini Katipamula-Malisetti, MD, a medical oncologist and hematologist with Minnesota Oncology who practices in Coon Rapids, has seen telehealth’s usefulness up close. During a pandemic, it can increase the number of touch points in areas such as survivorship care and nutrition, which would otherwise require a separate visit to the office.
Alternative Payment Models Can Stabilize and Improve Practice Radiation Reimbursement
February 14, 2022
Article
COVER FEATURE
How Value-based Care Is Changing Radiation Oncology for the Better
Emory’s Winship Joins AccessHope as Collaboration Partner
February 14, 2022
Article
FROM OUR PARTNERS
AccessHope is a program that allows patients and community oncologists to tap into the expertise of City of Hope, often through electronic sharing of records so the patient does not have to travel.
From Our Partners: Schleicher, Dickson Take New Roles at Tennessee Oncology
February 14, 2022
Article
FROM OUR PARTNERS
The changes come as Tennessee Oncology must now plan for a gap between the Oncology Care Model and a future alternative payment model from CMS.
Steven Pergam, MD, MPH, Discusses NCCN’s “Strong Preference” for mRNA Vaccines in Patients With Cancer to Prevent COVID-19
February 13, 2022
Article
A statement from NCCN’s Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis said that the panel “endorses vaccination for all eligible persons based on FDA-approved indications or emergency use authorization” and emphasized the need for everyone to be fully vaccinated—including third doses.
COA Survey: Practices Find OCM a Success; Some Added Services May Be at Risk
January 31, 2022
Article
FROM OUR PARTNERS
The Oncology Care Model (OCM) is set to expire June 30, 2022. With no successor on the horizon, respondents to a recent survey by the Community Oncology Alliance (COA) say features such as dedicated navigators and weekend appointments could be reduced or lost if revenues that supported them are eliminated.
NCCN Updates Give Zanubrutinib Preference in CLL/SLL
January 20, 2022
Article
Zanubrutinib is a second-generation Bruton tyrosine kinase (BTK) inhibitor that has fewer off-target effects and less cardiotoxicity than ibrutinib, a first-generation BTK inhibitor.
FCS’ Bailey Discusses 4-Drug Regimens, Use of MRD in Multiple Myeloma
January 03, 2022
Article
Ray Bailey, BPharm, RPh, senior vice president of Pharmacy Services for Florida Cancer Specialists (FCS) Pharmacy Services operations, spoke with The American Journal of Managed Care® (AJMC®) just after the conclusion of the 63rd American Society of Hematology Meeting & Exposition, which took place December 11-14, 2021.
McAndrew: No Reason Not to Start With CDK4/6 Inhibitors in Metastatic HR+ HER2-Negative Breast Cancer
December 20, 2021
Article
Nicholas McAndrew, MD, MSCE, a medical oncologist and breast cancer specialist at UCLA Health and assistant clinical professor of Medicine at UCLA in the Division of Hematology/Oncology, discusses the arrival of CDK4/6 inhibitors in the treatment landscape.